/
RCEL
$4.25+$0.28 (+7.05%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$122.2M
31M shares
52-week range
$3.22 – $7.12
26% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
ADRC
Borrow rate
20.26%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-16.30
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8M | $14.3M | $29.2M | $33.0M | $34.4M | $50.1M | $64.3M | $71.6M |
| Cost of revenue | $1.8M | $3.0M | $5.9M | $6.1M | $6.0M | $7.8M | $9.1M | $12.8M |
| Gross profit | $6.0M | $11.3M | $23.3M | $26.9M | $28.4M | $42.4M | $55.2M | $58.8M |
| Gross margin | 76.8% | 79.2% | 79.6% | 81.5% | 82.4% | 84.5% | 85.8% | 82.1% |
| R&D | $11.4M | $9.2M | $14.8M | $15.7M | $13.9M | $20.8M | $20.4M | $20.8M |
| Operating income | −$36.5M | −$42.7M | −$26.5M | −$25.1M | −$27.5M | −$42.7M | −$56.6M | −$42.5M |
| EBITDA | −$35.7M | −$41.5M | −$25.8M | −$24.4M | −$26.0M | −$33.5M | −$55.3M | −$41.2M |
| Net income | −$35.9M | −$42.0M | −$26.6M | −$25.1M | −$26.7M | −$35.4M | −$61.8M | −$48.6M |
| Net margin | -458.6% | -294.7% | -90.9% | -76.1% | -77.5% | -70.6% | -96.3% | -67.8% |
| EPS (diluted) | -1.60 | -2.07 | -1.17 | -1.03 | -1.07 | -1.40 | -2.39 | -1.74 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $82M | $-1.10 | $-1.17–$-1.03 | 4 |
| 2027 | $100M | $-0.69 | $-0.97–$-0.41 | 4 |
| 2028 | $123M | $-0.03 | $-0.08–$0.03 | 2 |
| 2029 | $411M | $2.76 | $2.59–$3.10 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Avita Medical, Inc. Common Stock
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
www.avitamedical.com- Employees
- 226
- IPO / List date
- Mar 8, 2012
- HQ
- VALENCIA, CA
Held by traders on TradeandTell
No one on the platform currently holds RCEL.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in RCEL as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded RCEL yet.
